Atlas chapter 19 · Metabolic / lipids

Oyster Mushroom

Pleurotus ostreatus

E3Ø — the grade-defining proposition has been tested directly in randomized, double-blind, controlled human evidence. The Ø qualifier records that the controlled evidence did not support the proposed LDL-lowering benefit. E is not downgraded because the result is null: a controlled null is evidence.Ø — Does not support under tested conditionsR2 — limited independent controlled repetition exists for the LDL-lowering proposition. Two genuinely independent randomized controlled programmes — Schneider et al. 2011 and Johnen et al. 2026 — used materially different P. ostreatus interventions and both failed to demonstrate LDL reduction. A third independent controlled study, Sayeed et al. 2014, reported a significant between-group LDL difference favouring P. ostreatus, but allocation was non-random and unblinded, attrition was severe and differential, risk of selection bias was high, statistical evaluation was limited, and LDL did not significantly decline within the mushroom group. The study therefore constitutes low-credibility contradictory controlled evidence rather than a robust positive replication. Multiple outcomes within one trial, post-hoc analyses, mechanistic findings and uncontrolled studies are not counted as independent replications.

Proposition / claim: LDL lowering from defined P. ostreatus interventions
Evidence owner: The grade-defining LDL evidence belongs to the defined Pleurotus ostreatus interventions actually tested, particularly the 2026 oven-dried fruiting-body powder beverage intervention. The earlier 2011 randomized P. ostreatus soup intervention provides limited convergent LDL-null repetition. Neither intervention automatically transfers its result to generic Oyster Mushroom products, other Pleurotus species, different preparations, doses, matrices or durations.
Dominant uncertainty: Whether any defined P. ostreatus intervention can reproducibly produce a clinically meaningful LDL reduction. The burden has shifted toward the positive claim because more than one randomized intervention has failed to demonstrate LDL lowering.

Organism: Oyster Mushroom
Tested intervention: Oven-dried Pleurotus ostreatus fruiting-body powder formulated into a blinded beverage granule, administered at 8.4 g/day and providing 3.0 g/day fungal beta-glucans for four weeks.
Evidence target: Standardized preparation
Intervention description: The grade-defining 2026 LDL trial used oven-dried P. ostreatus fruiting-body powder formulated into encoded, blinded beverage granules. Dose: 8.4 g/day P. ostreatus powder, providing 3.0 g/day fungal beta-glucans, for four weeks. The earlier 2011 randomized intervention used a materially different intervention: 30 g/day dried P. ostreatus delivered in soup for 21 days, compared with tomato soup. The two interventions are relevant to the same narrow LDL direction, but they are not chemically or clinically identical preparations. Evidence from either intervention must not automatically be transferred to arbitrary Oyster Mushroom powders, extracts, foods, supplements, doses or durations.
Population: Adults with moderately elevated LDL-C in the grade-defining 2026 trial: 46 participants, 37 female and 9 male, with baseline LDL-C 116-190 mg/dL. The earlier randomized trial involved a different population of 20 young adults and should be treated as limited corroborative LDL-direction evidence rather than an exact replication.
Comparator: Mushroom-free placebo beverage in the 2026 randomized, double-blind controlled trial. The earlier 2011 randomized study compared P. ostreatus soup with tomato soup. The grade-defining controlled contrast is the 2026 intervention versus placebo.
Outcome: Primary outcome: LDL-C. 2026 result: no significant between-group difference in LDL-C change; reported treatment contrast 4.5 mg/dL, 95% CI -5.5 to 13.1 mg/dL, P = 0.375. The intervention also did not significantly improve total cholesterol, HDL-C, triglycerides, ApoA1 or ApoB. Post-hoc cholesterol-absorption-marker findings are hypothesis-generating only; they do not reverse or rescue the prespecified primary LDL null. The earlier 2011 randomized study likewise did not demonstrate an LDL reduction, despite favourable changes in triglycerides and oxidized LDL.
Evidence maturity (E): E3Ø — the grade-defining proposition has been tested directly in randomized, double-blind, controlled human evidence. The Ø qualifier records that the controlled evidence did not support the proposed LDL-lowering benefit. E is not downgraded because the result is null: a controlled null is evidence.
Direction: Ø — Does not support under tested conditions
Historical flag (H): Not specified at dossier level
Replication (R): R2 — limited independent controlled repetition exists for the LDL-lowering proposition. Two genuinely independent randomized controlled programmes — Schneider et al. 2011 and Johnen et al. 2026 — used materially different P. ostreatus interventions and both failed to demonstrate LDL reduction. A third independent controlled study, Sayeed et al. 2014, reported a significant between-group LDL difference favouring P. ostreatus, but allocation was non-random and unblinded, attrition was severe and differential, risk of selection bias was high, statistical evaluation was limited, and LDL did not significantly decline within the mushroom group. The study therefore constitutes low-credibility contradictory controlled evidence rather than a robust positive replication. Multiple outcomes within one trial, post-hoc analyses, mechanistic findings and uncontrolled studies are not counted as independent replications.
Claim Gap (CG): CG0: A 2026 double-blind randomized controlled trial found no significant LDL-C reduction from 8.4 g/day P. ostreatus fruiting-body powder over four weeks. CG1: Current randomized evidence does not clearly support P. ostreatus as a reliable LDL-lowering intervention. CG2-3: "Oyster Mushroom may support cholesterol health." This wording is vague enough to move between distinct lipid outcomes and therefore introduces Outcome Substitution. CG4: "Oyster Mushroom lowers cholesterol naturally." This broad positive wording conflicts with the grade-defining LDL evidence. Claim ceiling: CG1 for current LDL evidence summaries.
Evidence Transfer Vector: Transferred proposition: "Oyster Mushroom reliably lowers LDL." ETV: I / D / R / O. I — Intervention: defined fruiting-body powder and soup interventions to generic Oyster Mushroom. D — Duration: short tested interventions to indefinite or general use. R — Replication: heterogeneous small studies to a reliable general effect. O — Outcome: broad "cholesterol" language to LDL-C specifically.
Taxonomic Transfer Confidence: HIGH for authenticated P. ostreatus. TTC is high when the tested material is securely identified as Pleurotus ostreatus. This does not establish equivalence across other Pleurotus species or across materially different P. ostreatus preparations.
Intervention Transfer Confidence: Defined trial preparations to generic Oyster Mushroom products: LOW-MODERATE. Transfer from the defined 2026 oven-dried fruiting-body powder beverage and the earlier soup intervention to arbitrary powders, extracts, supplements, foods, matrices, doses or durations is LOW-MODERATE. Species identity does not establish intervention equivalence.
Safety: S1-2. Oyster Mushroom has extensive culinary exposure and a generally reassuring food-safety context. Clinical-dose powders are not identical to ordinary dietary exposure, and concentrated or unusual preparations should not inherit unlimited safety certainty merely because the mushroom is commonly eaten.
Conservation: C0/C+. Pleurotus ostreatus is readily cultivated on straw, wood-derived and other lignocellulosic substrates. Commercial production does not require pressure on wild populations. Cultivability and ecological usefulness do not imply medicinal efficacy.
Resolution zone: RZ-2-3. The remaining question is confirmatory and proposition-specific. The priority is not another generic mechanistic or exploratory study.
Next best experiment: If the LDL proposition remains a research priority, conduct an independent, adequately powered controlled trial with LDL-C as the prespecified primary endpoint, using a fully characterized P. ostreatus preparation documenting fruiting-body identity, beta-glucan content, dose and batch. Any change in dose or duration must be prospectively justified. If the 2026 post-hoc cholesterol-absorption signal is proposed as a responsive-subgroup hypothesis, prespecify and test that hypothesis. Retrospective subgroup or mechanistic findings must not be used to rescue a failed primary LDL endpoint. The future experiment must allow the positive LDL claim to fail again.
Primary references: GRADE-OWNING / PRIMARY — CONTROLLED NULL (LDL). Johnen N, et al. Effects of oyster mushroom (Pleurotus ostreatus) consumption on blood lipids in adults with elevated LDL cholesterol: a randomized controlled trial. Nutrition & Metabolism. 2026;23(1):53. doi:10.1186/s12986-026-01122-3. PMID 42071226. PMCID PMC13147704. Registration DRKS00033943. Randomized, blinded, placebo-controlled; 46 adults; oven-dried fruiting-body powder beverage granule, 8.4 g/day supplying 3.0 g/day fungal beta-glucans, 28 days. Primary LDL-C between-group difference 4.5 mg/dL (95% CI -5.5 to 13.1; P = 0.375) — null.
PRIMARY — INDEPENDENT RANDOMIZED CONTROLLED NULL (LDL). Schneider I, Kressel G, Meyer A, Krings U, Berger RG, Hahn A. Lipid lowering effects of oyster mushroom (Pleurotus ostreatus) in humans. Journal of Functional Foods. 2011;3(1):17-24. doi:10.1016/j.jff.2010.11.004. No PMID or PMCID verified. Randomized, double-blind, placebo-controlled crossover; lyophilized P. ostreatus, 30 g/day in a soup matrix, 21 days. No significant LDL-cholesterol reduction.
CONTROLLED CONTRADICTORY — LDL; NON-RANDOMIZED; HIGH RISK OF BIAS. Sayeed MA, et al. Effect of edible mushroom (Pleurotus ostreatus) on lipid profile of hyperlipidaemic subjects. Ibrahim Medical College Journal. 2014;8(1):6-11. doi:10.3329/imcj.v8i1.22982. No PMID or PMCID verified. Fresh P. ostreatus, 200 g/day, food intervention, up to 360 days. Reported a favourable BETWEEN-group LDL result (P < 0.001), but the study's own WITHIN-group data show no LDL reduction in the mushroom group; allocation was non-random, the study was unblinded, attrition was severe and differential (~60%), and statistical evaluation was limited. Methodological credibility is substantially below the randomized trials; treated as low-credibility contradictory controlled evidence, not positive replication.
SYSTEMATIC REVIEW / SECONDARY SYNTHESIS — NOT AN INDEPENDENT REPLICATION. Dicks L, Ellinger S. Effect of the intake of oyster mushrooms (Pleurotus ostreatus) on cardiometabolic parameters — a systematic review of clinical trials. Nutrients. 2020;12(4):1134. doi:10.3390/nu12041134. PMID 32316680. PMCID PMC7230384. Species-specific synthesis; concludes the clinical evidence base for cardiometabolic benefit is small, heterogeneous in preparation and dose, and methodologically limited.
CONTEXTUAL / EXPLORATORY HUMAN EVIDENCE — UNCONTROLLED; NOT REPLICATION. Khatun K, Mahtab H, Khanam PA, Sayeed MA, Khan KA. Oyster mushroom reduced blood glucose and cholesterol in diabetic subjects. Mymensingh Medical Journal. 2007;16(1):94-99. PMID 17344789. Small before/after uncontrolled crossover in diabetic subjects; no randomized control group; contributes context on tolerability and lipid signals only, and owns no part of the grade.
CONTEXTUAL — PREPARATION AND CONSTITUENT CHARACTERIZATION. Beta-glucan and lovastatin content of Pleurotus ostreatus preparations varies markedly with strain, substrate, drying method and batch; strain identity, molecular authentication and batch characterization are absent or insufficiently reported in Schneider et al. 2011 and Sayeed et al. 2014, and only partially reported (beta-glucan dose, drying method) in Johnen et al. 2026. These details are not inferred.
GENEALOGY SUMMARY (bookkeeping, not an independent source). Publications bearing on the P. ostreatus LDL proposition: 4 primary human records (Johnen 2026, Schneider 2011, Sayeed 2014, Khatun 2007) plus 1 systematic review (Dicks & Ellinger 2020). Distinct trials: 4. Distinct cohorts: 4 (German adults with elevated LDL; German adults; Bangladeshi hyperlipidaemic adults; Bangladeshi diabetic adults). Independent research programmes: 3. Controlled LDL tests: 3. Randomized controlled LDL tests: 2 (both null). Uncontrolled studies: 1. Systematic reviews: 1. Mechanistic/preclinical work: extensive but owns no human grade. Multiple outcomes within a single trial are not counted as replication; no other mushroom species (notably Agaricus bisporus) contributes to the P. ostreatus grade.
Source chapter: Chapter 19, The Fungal Evidence Atlas